Genentech/Biogen Idec Submit Rituxan sBLAs For Arthritis, Front-Line NHL
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genentech and Biogen Idec’s Rituxan (rituximab) could be approved by February 2006 for aggressive non-Hodgkin’s lymphoma and rheumatoid arthritis.